First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial

BACKGROUND: The addition of nivolumab to trastuzumab and chemotherapy in first-line unresectable or metastatic HER2 positive esophagogastric adenocarcinoma (HER2+ EGA) results in long progression-free and overall survival as shown by the INTEGA (ipilimumab or FOLFOX in combination with nivolumab and...

Descripción completa

Detalles Bibliográficos
Autores principales: Paschold, Lisa, Stein, Alexander, Thiele, Benjamin, Tintelnot, Joseph, Henkes, Svenja-Sibylla, Coith, Cornelia, Schultheiß, Christoph, Pantel, Klaus, Riethdorf, Sabine, Binder, Mascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277145/
https://www.ncbi.nlm.nih.gov/pubmed/37328285
http://dx.doi.org/10.1136/jitc-2023-006678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277145/
https://www.ncbi.nlm.nih.gov/pubmed/37328285
http://dx.doi.org/10.1136/jitc-2023-006678

Ejemplares similares